145 related articles for article (PubMed ID: 27865544)
1. Central liver toxicity after SBRT: An expanded analysis and predictive nomogram.
Toesca DA; Osmundson EC; Eyben RV; Shaffer JL; Lu P; Koong AC; Chang DT
Radiother Oncol; 2017 Jan; 122(1):130-136. PubMed ID: 27865544
[TBL] [Abstract][Full Text] [Related]
2. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy.
Barry A; McPartlin A; Lindsay P; Wang L; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
Pract Radiat Oncol; 2017; 7(5):e331-e337. PubMed ID: 28442242
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities.
Lazarev S; Hardy-Abeloos C; Factor O; Rosenzweig K; Buckstein M
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2077-2083. PubMed ID: 30088143
[TBL] [Abstract][Full Text] [Related]
5. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
Toesca DAS; Osmundson EC; von Eyben R; Shaffer JL; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(3):173-182. PubMed ID: 28343896
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
7. Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose?
Tanguturi SK; Niemierko A; Wo JY; Nguyen KN; Prichard H; Zhu AX; Wolfgang JA; Hong TS
Pract Radiat Oncol; 2017; 7(5):e323-e329. PubMed ID: 28341320
[TBL] [Abstract][Full Text] [Related]
8. A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma.
Su TS; Luo R; Liang P; Cheng T; Zhou Y; Huang Y
Radiother Oncol; 2018 Oct; 129(1):136-142. PubMed ID: 29548558
[TBL] [Abstract][Full Text] [Related]
9. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.
Eriguchi T; Takeda A; Sanuki N; Oku Y; Aoki Y; Shigematsu N; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1006-11. PubMed ID: 23102838
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy for central lung tumors.
Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.
Que J; Kuo HT; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
BMC Cancer; 2016 Jul; 16():451. PubMed ID: 27405814
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Velec M; Haddad CR; Craig T; Wang L; Lindsay P; Brierley J; Brade A; Ringash J; Wong R; Kim J; Dawson LA
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):939-946. PubMed ID: 28333016
[TBL] [Abstract][Full Text] [Related]
13. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration.
Lee S; Kim H; Ji Y; Cho B; Kim SS; Jung J; Kwak J; Park JH; Lee SW; Kim JH; Yoon SM
Sci Rep; 2018 Nov; 8(1):16224. PubMed ID: 30385839
[TBL] [Abstract][Full Text] [Related]
15. Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma.
Dreher C; Høyer KI; Fode MM; Habermehl D; Combs SE; Høyer M
Acta Oncol; 2016 Jul; 55(7):886-91. PubMed ID: 26878669
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Body Radiation Therapy for Liver Lesions. A Single-institution Experience.
Caivano D; Bracci S; Russo I; Montalto A; Armosini V; De Sanctis V; Valeriani M; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Jul; 35(7):4171-5. PubMed ID: 26124374
[TBL] [Abstract][Full Text] [Related]
17. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
Stephans KL; Djemil T; Diaconu C; Reddy CA; Xia P; Woody NM; Greskovich J; Makkar V; Videtic GM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):197-202. PubMed ID: 25015204
[TBL] [Abstract][Full Text] [Related]
18. Development of deep neural network for individualized hepatobiliary toxicity prediction after liver SBRT.
Ibragimov B; Toesca D; Chang D; Yuan Y; Koong A; Xing L
Med Phys; 2018 Oct; 45(10):4763-4774. PubMed ID: 30098025
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study.
Méndez Romero A; Wunderink W; Hussain SM; De Pooter JA; Heijmen BJ; Nowak PC; Nuyttens JJ; Brandwijk RP; Verhoef C; Ijzermans JN; Levendag PC
Acta Oncol; 2006; 45(7):831-7. PubMed ID: 16982547
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
Goodman KA; Wiegner EA; Maturen KE; Zhang Z; Mo Q; Yang G; Gibbs IC; Fisher GA; Koong AC
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):486-93. PubMed ID: 20350791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
